Bionomics Has Been Granted European Patent EP3867252 Titled "6-INDAN-2-YLOXY-3-(MORPHOLINE-4-CARBONYL)-1,8-NAPHTHYRIDIN-4-ONE DERIVATIVES & SIMILAR COMPOUNDS AS MODULATORS OF THE ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR FOR THE TREATMENT OF ANXIETY"
Portfolio Pulse from Benzinga Newsdesk
Bionomics has been granted a European patent EP3867252 for its 6-INDAN-2-YLOXY-3-(MORPHOLINE-4-CARBONYL)-1,8-NAPHTHYRIDIN-4-ONE derivatives and similar compounds. These compounds are modulators of the Alpha 7 Nicotinic Acetylcholine Receptor and are used for the treatment of anxiety.
November 03, 2023 | 5:41 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
The granting of the European patent EP3867252 to Bionomics for its anxiety treatment compounds could potentially increase the company's market share in the European market.
The granting of a patent provides a company with exclusive rights to manufacture, sell, and use the patented product. This could potentially increase Bionomics' market share in the European market for anxiety treatment compounds, leading to increased revenues and potentially a positive impact on the company's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100